Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Johnson and Johnson
Colorcon
McKinsey
Baxter

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Claims for Patent: 10,160,747

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 10,160,747
Title:Compounds and methods for kinase modulation, and indications therefor
Abstract: Disclosed are compounds of Formula I(b): ##STR00001## or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein Ring A, Ring HD, J, each T, R.sup.3, R.sup.4, R.sup.5, each R.sup.7, and m are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.
Inventor(s): Lin; Jack (Hercules, CA), Ibrahim; Prabha N. (Mountain View, CA), Albers; Aaron (San Francisco, CA), Buell; John (San Francisco, CA), Guo; Zuojun (Pasadena, CA), Pham; Phuongly (San Francisco, CA), Powers; Hannah (San Francisco, CA), Shi; Songyuan (Fremont, CA), Spevak; Wayne (Berkeley, CA), Wu; Guoxian (Foster City, CA), Zhang; Jiazhong (Foster City, CA), Zhang; Ying (Fremont, CA), Wu; Jeffrey (Berkeley, CA)
Assignee: Plexxikon Inc. (Berkeley, CA)
Application Number:15/460,095
Patent Claims:1. A compound having Formula II(a) or II(b): ##STR00333## or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein: Ring A is phenyl, pyridyl, pyrimidinyl, or pyridazinyl; Y is N or CR.sup.9; R.sup.9 is hydrogen, halo, amino, alkyl optionally substituted with alkoxy or hydroxy, haloalkyl, or alkoxy; (i) is a single bond, wherein: Z.sup.1 is CH or N, Z.sup.2 is C(R.sup.12)(R.sup.12a) and Z.sup.3 is C(R.sup.13)(R.sup.13a); or Z.sup.1 is CH, Z.sup.2 is N(R.sup.12) and Z.sup.3 is C(R.sup.13)(R.sup.13a); or Z.sup.1 is CH, Z.sup.2 is C(R.sup.12)(R.sup.12a) and Z.sup.3 is N(R.sup.13); or (ii) is a double bond, wherein: Z.sup.1 is CH or N, Z.sup.2 is C(R.sup.12) and Z.sup.3 is C(R.sup.13); or Z.sup.1 is CH, Z.sup.2 is N and Z.sup.3 is C(R.sup.13); or Z.sup.1 is CH, Z.sup.2 is C(R.sup.12) and Z.sup.3 is N; R.sup.2 is ##STR00334## wherein: Ring B is a 5 or 6-membered saturated or unsaturated ring having 0-3 heteroatoms selected from O, N, and S; each Q is independently hydrogen, alkyl, halo, cyano, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, oxo, --R.sup.20OR.sup.21, --R.sup.20OR.sup.21, --R.sup.20OC(O)R.sup.21, --R.sup.20C(O)N(R.sup.24)(R.sup.25), --R.sup.20S(O).sub.tR.sup.22, --R.sup.20N(R.sup.24)(R.sup.25), or --R.sup.20N(R.sup.24)(R.sup.25), or --R.sup.20N(R.sup.24)C(O)R.sup.21, wherein each alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl or heterocycloalkylalkyl is independently optionally substituted with 1 to 3 groups each independently halo, oxo, amino, alkyl, haloalkyl or --R.sup.20OR.sup.21, Q.sup.1 is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, --R.sup.23OR.sup.21, --R.sup.23OR.sup.23OR.sup.21, --R.sup.23C(O)R.sup.21, --R.sup.23N(R.sup.24)(R.sup.25), --R.sup.23OC(O)R.sup.21, --R.sup.23C(O)OR.sup.21, --R.sup.23C(O)N(R.sup.24)(R.sup.25), or --R.sup.23S(O).sub.tR.sup.22 , wherein each alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl or heterocycloalkylalkyl is independently optionally substituted with 1 to 3 groups each independently halo, oxo, amino, alkyl, haloalkyl or --R.sup.20OR.sup.21; each Q.sup.3 is independently hydrogen, cyano, --S --C.sub.1-C.sub.2 alkyl, halo, C.sub.2-C.sub.3 alkenyl, C.sub.2-C.sub.3 alkynyl, C.sub.1-C.sub.3 alkoxy, cyclopropyl, amino, --N(H)(C.sub.1-C.sub.3alkyl), --N(H)C(O)C(H)=CH.sub.2 or C.sub.1-C.sub.3 alkyl, wherein each Q.sup.3 is optionally substituted with 1-3 substituents each independently halo, hydroxy or methoxy; Q.sup.4 is hydrogen, cyclopropyl, C.sub.1 -C.sub.4 alkoxy, or C.sub.1-C.sub.4 alkyl optionally substituted with 1-3 substituents each independently halo, hydroxy or methoxy; each R.sup.20 is independently alkylene, alkenylene, alkynylene or a direct bond; each R.sup.21 is independently hydrogen, alkyl, haloalkyl, alkenyl, alkynyl or cycloalkyl; each R.sup.22 is independently alkyl, haloalkyl, alkenyl, alkynyl or cycloalkyl; each R.sup.23 is independently alkylene, alkenylene or alkynylene; R.sup.24 and R.sup.25 are each independently hydrogen or alkyl; a is an integer from 0 to 3; each t is independently 0, 1 or 2; R.sup.3 is hydrogen or C.sub.1-C.sub.6 alkyl; each R.sup.6 is independently hydrogen, halo, C.sub.1-C.sub.3alkyl, or C.sub.1-C.sub.3 alkoxy; each R.sup.7 is independently C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6alkoxy, C.sub.3-C.sub.6 cycloalkyl, 4-6 membered heterocycloalkyl, C.sub.3-C.sub.6cycloalkylalkyl, --S(O).sub.2alkyl, or a 4-6 membered heterocycloalkyl-C.sub.1-C.sub.6 alkyl, wherein each R.sup.7 is optionally substituted with 1 to 3 groups each independently hydroxy, halo, C.sub.1-C.sub.6 alkyl, cyano or C.sub.1-C.sub.6 haloalkyl; R.sup.9a is hydrogen, halo, hydroxy-C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkyl, or C.sub.1-C.sub.6 alkoxy-C.sub.1-C.sub.6 alkyl; each R.sup.11 is independently a 5-6 membered heterocycloalkyl, cyano, C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6alkyl, C.sub.1-C.sub.6 haloalkyl, --C(O)OCH.sub.3, or --C(O)OH; R.sup.10 is C.sub.1-C.sub.6 alkyl, hydroxy-C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6alkoxy-C.sub.1-C.sub.6 alkyl, 5-membered heteroaryl optionally substituted with alkyl, C.sub.3-C.sub.6 cycloalkyl, --C(O)OCH.sub.3, or --C(O)OH; R.sup.12 is hydrogen, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy, --(CH.sub.2).sub.0-2--N(R.sup.1b).sub.2, halo, C.sub.3-C.sub.6 cycloalkyl, --C(O)--C.sub.3-C.sub.6cycloalkyl, phenyl optionally substituted with 1-2 R.sup.11 groups, 5-6 membered heteroaryl optionally substituted with 1-2 R.sup.11 groups, or alkynyl optionally substituted with R.sup.10; R.sup.13 is hydrogen, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy, --C(O)--C.sub.1-C.sub.4 alkyl, halo, cyano, --(CH.sub.2).sub.0-2--N(R.sup.1b).sub.2, --C(O)NHCH.sub.3, amino, --NHC(O)CF.sub.3, C.sub.3-C.sub.6 cycloalkyl, --C(O)--C.sub.3-C.sub.6 cycloalkyl, phenyl optionally substituted with 1-2 R.sup.11 groups, 5-6 membered heteroaryl optionally substituted with 1-2 R.sup.11 groups, or alkynyl optionally substituted with R.sup.10; each R.sup.1b is independently hydrogen or alkyl; R.sup.12a is hydrogen; or R.sup.12 and R.sup.12a, together with the carbon to which they are attached, join to form a C.sub.3-6 spirocycloalkyl; or R.sup.12 and R.sup.12a form an oxo group; R.sup.13a is hydrogen; or R.sup.13 and R.sup.13a, together with the carbon to which they are attached, join to form a C.sub.3-6 spirocycloalkyl; or R.sup.13 and R.sup.13a form an oxo group; and m is 0, 1 or 2.

2. The compound of claim 1, wherein: R.sup.3 is hydrogen; each R.sup.6 is independently chloro, fluoro, methoxy, or methyl; each R.sup.7 is independently C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl, C.sub.1-C.sub.3 alkoxy, hydroxy-C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.3alkoxy-C.sub.1-C.sub.3alkyl, C.sub.3-C.sub.6 cycloalkyl, 4-6 membered heterocycloalkyl, C.sub.3-C.sub.6 cycloalkylalkyl, or a 4-6 membered heterocycloalkyl-C.sub.1-C.sub.6 alkyl; and m is 1 or 2.

3. The compound of claim 1 having Formula III(a): ##STR00335## or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein each R.sup.6a is independently hydrogen or fluoro.

4. The compound of claim 1 having Formula III(b) or III(c): ##STR00336## or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein each R.sup.6a is independently hydrogen or fluoro.

5. The compound of claim 1, wherein: Ring A is pyridyl or phenyl; and each R.sup.6 is hydrogen or one R.sup.6 is halo, alkyl or alkoxy.

6. The compound of claim 1, wherein: ##STR00337## is: ##STR00338## wherein: R.sup.7a is C.sub.1-C.sub.4 alkoxy, C.sub.1-C.sub.4 alkyl optionally substituted with cyano, C.sub.1-C.sub.4 haloalkyl, cyclopropyl, halo, morpholinyl or cyano; and R.sup.7b is C.sub.1-C.sub.4 alkoxy, C.sub.1-C.sub.4 alkyl optionally substituted with cyano, C.sub.1-C.sub.4 haloalkyl, halo or cyano.

7. The compound of claim 1, wherein: ##STR00339## wherein: R.sup.7a is cyclopropyl, --OCH.sub.3, --CH.sub.3, --CH.sub.2F, --CHF.sub.2, --CF.sub.3, --OCF.sub.3, --C(CH.sub.3).sub.3, --C(CN)(CH.sub.3).sub.2, F, Cl, Br, or cyano; and R.sup.7b is cyclopropyl, --OCH.sub.3, --CH.sub.3, --CH.sub.2F, --CHF.sub.2, --CF.sub.3, --C(CH.sub.3).sub.3, --C(CN)(CH.sub.3).sub.2, --OCF.sub.3, F, Cl, Br or cyano.

8. The compound of claim 1, wherein: ##STR00340## is: ##STR00341##

9. The compound of claim 1, wherein R.sup.2 is: ##STR00342##

10. The compound of claim 1, wherein R.sup.2 is: ##STR00343## wherein: each Q is independently hydrogen, --OCH.sub.3, hydroxy-C.sub.1-C.sub.4 alkyl, --CF.sub.3, --CHF.sub.2, --CH.sub.2F, --CH.sub.2CH.sub.3, or --CH.sub.3; Q.sup.1 is hydrogen, hydroxy-C.sub.1-C.sub.4 alkyl, --CF.sub.3, --CHF.sub.2, --CH.sub.2F, --CH.sub.2CH.sub.3, or --CH.sub.3; each Q.sup.3 is independently hydrogen, --OCH.sub.3, hydroxy-C.sub.1-C.sub.3 alkyl, --CF.sub.3, --CHF.sub.2, --CH.sub.2F, --CH.sub.2CH.sub.3, or --CH.sub.3; and Q.sup.4 is hydrogen, hydroxy-C.sub.1-C.sub.4 alkyl, --CF.sub.3, --CHF.sub.2, --CH.sub.2F,--CH.sub.2CH.sub.3, or --CH.sub.3.

11. The compound of claim 1, wherein R.sup.2 is: ##STR00344##

12. The compound of claim 1, wherein: R.sup.12 is hydrogen; --CH.sub.3; Cl; F; Br; cyclopropyl; phenyl; pyridyl optionally substituted with morpholinyl, ethoxy, methoxy, cyano, --CF.sub.3, --CHF.sub.2, --CH.sub.2F or --CH.sub.3; ethynyl optionally substituted with --C(CH.sub.3).sub.3, --C(CH.sub.3).sub.2OH, cyclopropyl, --C(O)OCH.sub.3, --C(O)OH, or methoxymethyl; or imidazolyl optionally substituted with methyl, --C(O)OCH.sub.3, or --C(O)OH; and R.sup.13 is hydrogen, --C(O)CH.sub.3, --C(O)CH.sub.2CH.sub.3, F, Cl, Br, cyano, cyclopropyl, --C(O)-cyclopropyl, --C(O)NHCH.sub.3, --OCH.sub.3, --OCH.sub.2CH.sub.3, --CH.sub.2CH.sub.3, amino, or --NHC(O)CF.sub.3.

13. The compound of claim 1, wherein: R.sup.12 is phenyl; pyridyl optionally substituted with morpholinyl, ethoxy, methoxy, cyano, --CF.sub.3, --CHF.sub.2, --CH.sub.2F, or --CH.sub.3; or ethynyl optionally substituted with --C(CH.sub.3).sub.3, --C(CH.sub.3).sub.2OH, cyclopropyl, --C(O)OCH.sub.3, --C(O)OH, or methoxymethyl; and R.sup.13 is hydrogen, --C(O)CH.sub.3, --C(O)CH.sub.2CH.sub.3, F, Cl, Br, cyano, cyclopropyl, --C(O)-cyclopropyl, --C(O)NHCH.sub.3, --OCH.sub.3, --OCH.sub.2CH.sub.3, --CH.sub.2CH.sub.3, amino, or --NHCOCF.sub.3.

14. The compound of claim 4 having Formula III(b): ##STR00345## or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein: R.sup.12 is phenyl; pyridyl optionally substituted with morpholinyl, ethoxy, methoxy, cyano, --CF.sub.3, --CHF.sub.2, --CH.sub.2F, or --CH.sub.3; or ethynyl optionally substituted with --C(CH.sub.3).sub.3, --C(CH.sub.3).sub.2OH, cyclopropyl, --C(O)OCH.sub.3, --C(O)OH or methoxymethyl; and R.sup.13 is hydrogen.

15. The compound of claim 4 having Formula III(c): ##STR00346## or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein R.sup.13 is --C(O)CH.sub.3, --C(O)CH.sub.2CH.sub.3, F, Cl, Br, cyano, cyclopropyl, --C(O)-cyclopropyl, --C(O)NHCH.sub.3, --OCH.sub.3, --OCH.sub.2CH.sub.3, --CH.sub.2CH.sub.3, amino, or --NHC(O)CF.sub.3.

16. A compound selected from: TABLE-US-00011 No. Compound Structure P-0001 ##STR00347## P-0002 ##STR00348## P-0003 ##STR00349## P-0004 ##STR00350## P-0005 ##STR00351## P-0006 ##STR00352## P-0007 ##STR00353## P-0008 ##STR00354## P-0009 ##STR00355## P-0010 ##STR00356## P-0011 ##STR00357## P-0012 ##STR00358## P-0013 ##STR00359## P-0014 ##STR00360## P-0015 ##STR00361## P-0016 ##STR00362## P-0017 ##STR00363## P-0018 ##STR00364## P-0019 ##STR00365## P-0020 ##STR00366## P-0021 ##STR00367## P-0022 ##STR00368## P-0023 ##STR00369## P-0024 ##STR00370## P-0025 ##STR00371## P-0026 ##STR00372## P-0027 ##STR00373## P-0028 ##STR00374## P-0029 ##STR00375## P-0030 ##STR00376## P-0031 ##STR00377## P-0032 ##STR00378## P-0033 ##STR00379## P-0034 ##STR00380## P-0035 ##STR00381## P-0036 ##STR00382## P-0037 ##STR00383## P-0038 ##STR00384## P-0039 ##STR00385## P-0040 ##STR00386## P-0041 ##STR00387## P-0042 ##STR00388## P-0043 ##STR00389## P-0044 ##STR00390## P-0045 ##STR00391## P-0046 ##STR00392## P-0047 ##STR00393## P-0048 ##STR00394## P-0049 ##STR00395## P-0050 ##STR00396## P-0051 ##STR00397## P-0052 ##STR00398## P-0053 ##STR00399## P-0054 ##STR00400## P-0055 ##STR00401## P-0056 ##STR00402## P-0057 ##STR00403## P-0058 ##STR00404## P-0059 ##STR00405## P-0060 ##STR00406## P-0061 ##STR00407## P-0062 ##STR00408## P-0063 ##STR00409## P-0064 ##STR00410## P-0065 ##STR00411## P-0066 ##STR00412## P-0067 ##STR00413## P-0068 ##STR00414## P-0069 ##STR00415## P-0070 ##STR00416## P-0071 ##STR00417## P-0072 ##STR00418## P-0073 ##STR00419## P-0074 ##STR00420## P-0075 ##STR00421## P-0076 ##STR00422## P-0077 ##STR00423## P-0078 ##STR00424## P-0079 ##STR00425## P-0080 ##STR00426## P-0081 ##STR00427## P-0082 ##STR00428## P-0083 ##STR00429## P-0084 ##STR00430## P-0085 ##STR00431## P-0086 ##STR00432## P-0087 ##STR00433## P-0088 ##STR00434## P-0089 ##STR00435## P-0090 ##STR00436## P-0091 ##STR00437## P-0092 ##STR00438## P-0093 ##STR00439## P-0094 ##STR00440## P-0095 ##STR00441## P-0096 ##STR00442## P-0097 ##STR00443## P-0098 ##STR00444## P-0099 ##STR00445## P-0100 ##STR00446## P-0101 ##STR00447## P-0102 ##STR00448## P-0103 ##STR00449## P-0104 ##STR00450## P-0105 ##STR00451## P-0106 ##STR00452## P-0107 ##STR00453## P-0108 ##STR00454## P-0109 ##STR00455## P-0110 ##STR00456## P-0111 ##STR00457## P-0112 ##STR00458## P-0113 ##STR00459## P-0116 ##STR00460## P-0117 ##STR00461## P-0118 ##STR00462## P-0119 ##STR00463## P-0120 ##STR00464## P-0121 ##STR00465## P-0122 ##STR00466## P-0130 ##STR00467## P-0131 ##STR00468## P-0133 ##STR00469## P-0134 ##STR00470##

P-0135 ##STR00471## P-0136 ##STR00472## P-0137 ##STR00473## P-0270 ##STR00474## P-0272 ##STR00475## P-0274 ##STR00476## P-0138 ##STR00477## P-0139 ##STR00478## P-0140 ##STR00479## P-0141 ##STR00480## P-0142 ##STR00481## P-0143 ##STR00482## P-0144 ##STR00483## P-0145 ##STR00484## P-0146 ##STR00485## P-0147 ##STR00486## P-0148 ##STR00487## P-0149 ##STR00488## P-0150 ##STR00489## P-0151 ##STR00490## P-0152 ##STR00491## P-0153 ##STR00492## P-0154 ##STR00493## P-0155 ##STR00494## P-0156 ##STR00495## P-0157 ##STR00496## P-0158 ##STR00497## P-0163 ##STR00498## P-0164 ##STR00499## P-0165 ##STR00500## P-0166 ##STR00501## P-0167 ##STR00502## P-0168 ##STR00503## P-0169 ##STR00504## P-0170 ##STR00505## P-0171 ##STR00506## P-0172 ##STR00507## P-0173 ##STR00508## P-0174 ##STR00509## P-0175 ##STR00510## P-0176 ##STR00511## P-0177 ##STR00512## P-0178 ##STR00513## P-0179 ##STR00514## P-0180 ##STR00515## P-0181 ##STR00516## P-0182 ##STR00517## P-0183 ##STR00518## P-0184 ##STR00519## P-0185 ##STR00520## P-0186 ##STR00521## P-0187 ##STR00522## P-0188 ##STR00523## P-0189 ##STR00524## P-0190 ##STR00525## P-0191 ##STR00526## P-0192 ##STR00527## P-0193 ##STR00528## P-0194 ##STR00529## P-0195 ##STR00530## P-0196 ##STR00531## P-0197 ##STR00532## P-0198 ##STR00533## P-0199 ##STR00534## P-0200 ##STR00535## P-0201 ##STR00536## P-0202 ##STR00537## P-0203 ##STR00538## P-0204 ##STR00539## P-0205 ##STR00540## P-0206 ##STR00541## P-0207 ##STR00542## P-0208 ##STR00543## P-0209 ##STR00544## P-0210 ##STR00545## P-0211 ##STR00546## P-0212 ##STR00547## P-0213 ##STR00548## P-0214 ##STR00549## P-0215 ##STR00550## P-0216 ##STR00551## P-0217 ##STR00552## P-0218 ##STR00553## P-0219 ##STR00554## P-0220 ##STR00555## P-0221 ##STR00556## P-0222 ##STR00557## P-0223 ##STR00558## P-0224 ##STR00559## P-0225 ##STR00560## P-0226 ##STR00561## P-0227 ##STR00562## P-0228 ##STR00563## P-0229 ##STR00564## P-0230 ##STR00565## P-0231 ##STR00566## P-0232 ##STR00567## P-0233 ##STR00568## P-0234 ##STR00569## P-0235 ##STR00570## P-0236 ##STR00571## P-0237 ##STR00572## P-0238 ##STR00573## P-0239 ##STR00574## P-0240 ##STR00575## P-0241 ##STR00576## P-0242 ##STR00577## P-0243 ##STR00578## P-0244 ##STR00579## P-0245 ##STR00580## P-0246 ##STR00581## P-0247 ##STR00582## P-0248 ##STR00583## P-0249 ##STR00584## P-0250 ##STR00585## P-0251 ##STR00586## P-0252 ##STR00587## P-0253 ##STR00588## P-0254 ##STR00589## P-0255 ##STR00590## P-0256 ##STR00591## P-0257 ##STR00592## P-0258 ##STR00593## P-0259 ##STR00594## P-0260 ##STR00595##

P-0261 ##STR00596## P-0262 ##STR00597## P-0263 ##STR00598## P-0264 ##STR00599## P-0265 ##STR00600## P-0266 ##STR00601## P-0267 ##STR00602## P-0268 ##STR00603## P-0269 ##STR00604## P-0271 ##STR00605## P-0273 ##STR00606##

or a pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt, deuterated analog, a tautomer or a stereoisomer thereof, and a pharmaceutically acceptable carrier.

18. The pharmaceutical composition of claim 17 further comprising a second pharmaceutical agent selected from the group consisting of an anti-proliferative agent, an anti-inflammatory agent, an immunomodulatory agent and an immunosuppressive agent.

19. The pharmaceutical composition according to claim 18, wherein the second pharmaceutical agent is i) an alkylating agent selected from adozelesin, altretamine, bizelesin, busulfan, carboplatin, carboquone, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, estramustine, fotemustine, hepsulfam, ifosfamide, improsulfan, irofulven, lomustine, mechlorethamine, melphalan, oxaliplatin, piposulfan, semustine, streptozocin, temozolomide, thiotepa, and treosulfan; ii) an antibiotic selected from bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, menogaril, mitomycin, mitoxantrone, neocarzinostatin, pentostatin, and plicamycin; iii) an antimetabolite selected from the group consisting of azacitidine, capecitabine, cladribine, clofarabine, cytarabine, decitabine, floxuridine, fludarabine, 5-fluorouracil, ftorafur, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, nelarabine, pemetrexed, raltitrexed, thioguanine, and trimetrexate; iv) an antibody therapy agent selected from alemtuzumab, bevacizumab, cetuximab, galiximab, gemtuzumab, nivolumab, panitumumab, pembrolizumab, pertuzumab, rituximab, tositumomab, trastuzumab, and 90 Y ibritumomab tiuxetan; v) a hormone or hormone antagonist selected from the group consisting of anastrozole, androgens, buserelin, diethylstilbestrol, exemestane, flutamide, fulvestrant, goserelin, idoxifene, letrozole, leuprolide, magestrol, raloxifene, tamoxifen, and toremifene; vi) a taxane selected from DJ-927, docetaxel, TPI 287, paclitaxel and DHA-paclitaxel; vii) a retinoid selected from alitretinoin, bexarotene, fenretinide, isotretinoin, and tretinoin; viii) an alkaloid selected from etoposide, homoharringtonine, teniposide, vinblastine, vincristine, vindesine, and vinorelbine; ix) an antiangiogenic agent selected from AE-941 (GW786034, Neovastat), ABT-510, 2-methoxyestradiol, lenalidomide, and thalidomide; x) a topoisomerase inhibitor selected from amsacrine, edotecarin, exatecan, irinotecan, SN-38 (7-ethyl-10-hydroxy-camptothecin), rubitecan, topotecan, and 9-aminocamptothecin; xi) a kinase inhibitor selected from erlotinib, gefitinib, flavopiridol, imatinib mesylate, lapatinib, sorafenib, sunitinib malate, AEE-788, AG-013736, AMG 706, AMN107, BMS-354825, BMS-599626, UCN-01 (7-hydroxystaurosporine), vemurafenib, dabrafenib, trametinib, cobimetinib selumetinib and vatalanib; xii) a targeted signal transduction inhibitor selected from bortezomib, geldanamycin, and rapamycin; xiii) a biological response modifier selected from imiquimod, interferon-.alpha.and interleukin-2; xiv) an IDO inhibitor; xv) a chemotherapeutic agent selected from 3-AP (3-amino-2-carboxyaldehyde thiosemicarbazone), altrasentan, aminoglutethimide, anagrelide, asparaginase, bryostatin-1, cilengitide, elesclomol, eribulin mesylate (E7389), ixabepilone, lonidamine, masoprocol, mitoguanazone, oblimersen, sulindac, testolactone, tiazofurin, a mTOR inhibitor, a PI3K inhibitor, a Cdk4 inhibitor, an Akt inhibitor, a Hsp90 inhibitor, a farnesyltransferase inhibitor or an aromatase inhibitor (anastrozole letrozole exemestane); xvi) a Mek inhibitor; xvii) a tyrosine kinase inhibitor; or xviii) an EGFR inhibitor.

20. A method for treatment of a disease or condition modulated by FLT3, CSF1R, or c-kit, wherein the disease is an inflammatory disease, an inflammatory condition, an autoimmune disease or cancer, said method comprising administering to a subject suffering from the disease a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, deuterated analog, a tautomer or a stereoisomer thereof.

21. A method for treating a subject with a disease or condition mediated by FLT3, CSF1R or c-kit, said method comprising administering to the subject an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, deuterated analog, a tautomer or a stereoisomer thereof, wherein the disease or condition is acute myeloid leukemia, stem cell ablation and myelopreparation for stem cell transplant, primary progressive multiple sclerosis, Erdheim-Chester Disease, Langerhans cell histocytosis, hairy cell leukemia, HIV, glioblastoma, anterior or posterior eye disease, lysosomal storage diseases, complex regional pain syndrome, neuro-inflammation, neuroinflammatory disorders, binswager type dementia, dementia with lewy bodie, cerebral palsy, progressive supranuclear palsy, vascular dementias, multi infarct dementia, fronto temporal dementia, pseudo-dementia, bladder cancer, basal cell carcinoma, cholangiocarcinoma, colon cancer, endometrial cancer, esophageal cancer, Ewing's sarcoma, gastric cancer, glioma, hepatocellular carcinoma, Hodgkin lymphoma, laryngeal carcinoma, leukemia, liver cancer, lung cancer, melanoma, mesothelioma, pancreatic cancer, rectal cancer, renal cancer, squamous cell carcinoma, T cell lymphoma, thyroid cancer, monocytic leukemia, pheochromocytoma, malignant peripheral nerve cell tumors, malignant peripheral nerve sheath tumors (MPNST), cutaneous and plexiform neurofibromas, leiomyoadenomatoid tumor, fibroids, uterine fibroids, leiomyosarcoma, papillary thyroid cancer, anaplastic thyroid cancer, medullary thyroid cancer, follicular thyroid cancer, hurthle cell carcinoma, thyroid cancer, ascites, malignant ascites, mesothelioma, salivary gland tumors, mucoepidermoid carcinoma of the salivary gland, acinic cell carcinoma of the salivary gland, gastrointestinal stromal tumors (GIST), tumors that cause effusions in potential spaces of the body, pleural effusions, pericardial effusions, peritoneal effusions aka ascites, giant cell tumors (GCT), GCT of bone other sarcomas, tumor angiogenesis, paracrine tumor growth or tumors that express aberrantly or otherwise a FLT3 ligand, or activating mutations or translocations of any of the foregoing.

22. A method for treating a subject with a disease or condition mediated by a FLT3, CSF1R or c-kit, said method comprising administering to the subject an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, deuterated analog, a tautomer or a stereoisomer thereof, wherein the disease or condition is lysosomal storage selected from the group consisting of mucolipodosis, alpha-mannosidosis; aspartylglucosaminuria; Batten disease; beta-mannosidosis; cystinosis; Danon disease; Fabry disease; Farber disease; fucosidosis; galactosialidosis; Gaucher disease; gangliosidosis; Krabbe disease; metachromatic leukodystrophy; mucopolysaccharidoses disorders; aspartylglucosaminuria; Batten disease; beta-mannosidosis; cystinosis; Danon disease; Fabry disease; Farber disease; fucosidosis; galactosialidosis; Gaucher disease; gangliosidosis; Krabbe disease; metachromatic leukodystrophy; mucopolysaccharidoses disorders; mucolipidosis type I (Sialidosis); Mucolipidosis type II (I-Cell disease); Mucolipidosis type III (Pseudo-Hurler polydystrophy); Mucolipidosis type IV; multiple sulfatase deficiency; Niemann-Pick types A, B, C; Pompe disease (glycogen storage disease); pycnodysostosis; Sandhoff disease; Schindler disease; Salla disease/sialic acid storage disease; Tay-Sachs; and Wolman disease.

23. The method of claim 20, wherein FLT3 kinase is a mutated form comprising a FLT3 internal tandem duplication (ITD) mutation.

24. The method of claim 23, wherein mutated FLT3 kinase further comprises a D835 mutation, a F691L mutation, or both D835 and F691L mutations.

25. The method according to claim 24, wherein mutated FLT3 kinase further comprises a D835Y mutation, a F691L mutation, or both D835Y and F691L mutations.

Details for Patent 10,160,747

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial Plexxikon Inc. (Berkeley, CA) 2036-03-16 RX search
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   Start Trial Plexxikon Inc. (Berkeley, CA) 2036-03-16 RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Plexxikon Inc. (Berkeley, CA) 2036-03-16 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Plexxikon Inc. (Berkeley, CA) 2036-03-16 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 002 2001-05-07   Start Trial Plexxikon Inc. (Berkeley, CA) 2036-03-16 RX Orphan search
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07   Start Trial Plexxikon Inc. (Berkeley, CA) 2036-03-16 RX Orphan search
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial Plexxikon Inc. (Berkeley, CA) 2036-03-16 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
AstraZeneca
Mallinckrodt
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.